News

The founders of include Pliant Therapeutics researchers from the University of California, San Francisco (UCSF) who have discovered crucial insights into the biology behind fibrosis and The researchers

During the trial, patients given 1.8 mg and 1.2 mg doses of the beloranib drug experienced 12.7% and 13.5% reduction in body weight, respectively. Patients given a placebo

The headline data dose-setting trial for the vaccine, GrassMATAMPL, is anticipated at the end of the first half of this year. The results of that will lead on

The trial is progressing quickly with only one more patient cohort of four patients to treat. Spinal fusion is the current standard of care for degenerative disc disease

In addition to OrbiMed, Deerfield Management Company and founding investors Atlas Venture and New Enterprise Associates (NEA) also participated in the financing. Synlogic CEO Jose Carlos Gutiérrez-Ramos "We

Early-onset LAMA2-related muscular dystrophy occurs in approximately 1 in 30,000 individuals and accounts for between 30 and 40 percent of total cases of congenital muscular dystrophy. TXA127 is

bb2121 is a chimeric antigen receptor T cell (CAR T) therapy targeting B cell maturation antigen (BCMA), and bluebird bio is developing bb2121 in collaboration with Celgene Corporation.

The agency’s letter stated that the company’s application was not sufficiently complete and it is seeking additional supporting information. There was no comment on the acceptability of the

The designation, which is meant to expedite the development of therapies that provide benefits over existing options, was based on an early clinical data from a phase I